Chugai Pharmaceutical Co Ltd (TSE:4519) Stock Price, Trades & News

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).

Financial Strength

8/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	No Debt
Equity-to-Asset	0.84
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	22.53	Distress Grey Safe
Beneish M-Score	-2.27	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-0.1
	3-Year EBITDA Growth Rate	4
	3-Year EPS without NRI Growth Rate	12.4
	3-Year FCF Growth Rate	16.8
	3-Year Book Growth Rate	12.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	15.9
	Future 3-5Y Total Revenue Growth Rate Estimate	10

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	30.98
	9-Day RSI	37.66
	14-Day RSI	40.37
	3-1 Month Momentum %	-13.22
	6-1 Month Momentum %	-11.7
	12-1 Month Momentum %	8.97

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.7
	Quick Ratio	3.82
	Cash Ratio	2.59
	Days Inventory	253.48
	Days Sales Outstanding	99.54
	Days Payable	91.62

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.87
	Dividend Payout Ratio	0.44
	3-Year Dividend Growth Rate	16.1
	Forward Dividend Yield %	1.79
	5-Year Yield-on-Cost %	3.96
	Shareholder Yield %	1.87

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	71.45
	Operating Margin %	48.09
	Net Margin %	35.02
	EBITDA Margin %	48.03
	FCF Margin %	25.72
	OCF Margin %	34.2
	ROE %	23.27
	ROA %	19.95
	ROIC %	38.31
	3-Year ROIIC %	27.7
	ROC (Joel Greenblatt) %	75.15
	ROCE %	31.47
	Years of Profitability over Past 10-Year	10
	Moat Score	6
	Tariff Resilience Score	7

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	26.31
	Forward PE Ratio	23.37
	PE Ratio without NRI	26.16
	Shiller PE Ratio	44.91
	Price-to-Owner-Earnings	37.61
	PEG Ratio	2.13
	PS Ratio	9.22
	PB Ratio	6.23
	Price-to-Tangible-Book	6.43
	Price-to-Free-Cash-Flow	35.83
	Price-to-Operating-Cash-Flow	26.94
	EV-to-EBIT	17.82
	EV-to-Forward-EBIT	16.71
	EV-to-EBITDA	17.82
	EV-to-Forward-EBITDA	16.04
	EV-to-Revenue	8.56
	EV-to-Forward-Revenue	8.3
	EV-to-FCF	34.06
	Price-to-GF-Value	0.93
	Price-to-Projected-FCF	2.37
	Price-to-DCF (Earnings Based)	0.69
	Price-to-DCF (FCF Based)	0.94
	Price-to-Median-PS-Value	1.33
	Price-to-Peter-Lynch-Fair-Value	2.55
	Price-to-Graham-Number	2.74
	Price-to-Net-Current-Asset-Value	10.07
	Price-to-Net-Cash	24.15
	Earnings Yield (Greenblatt) %	5.61
	FCF Yield %	2.79
	Forward Rate of Return (Yacktman) %	12.59

Financials (Next Earnings Date:2026-07-24)

Annual Quarterly TTM

TSE:4519's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Chugai Pharmaceutical Co Ltd Executives

Details

GF Value™: 円7735.19

TSE:4519

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 4519. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil 円)	1,291,229
	EPS (TTM) (円)	274.77
	Beta	0.382
	3-Year Sharpe Ratio	0.71
	3-Year Sortino Ratio	1.34
	Volatility %	38.19
	14-Day RSI	40.37
	14-Day ATR (円)	220.409572
	20-Day SMA (円)	7482.4
	12-1 Month Momentum %	8.97
	52-Week Range (円)	5942 - 10700
	Shares Outstanding (Mil)	1,645.76

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Chugai Pharmaceutical Co Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Chugai Pharmaceutical Co Ltd Stock Events

Financials Calendars

Event	Date	Price (円)
JPY 66.000000 Cash Dividend	2026-12-29	In 168 days
Third quarter earnings conference call for 2026	2026-10-27 18:00	In 106 days
Third quarter earnings results for 2026	2026-10-27 17:00	In 106 days
Second quarter earnings conference call for 2026	2026-07-24 17:00	In 11 days
Second quarter earnings results for 2026	2026-07-24 16:00	In 11 days
JPY 66.000000 Cash Dividend	2026-06-29	7,434.00 (-0.54%)
First quarter earnings conference call for 2026	2026-04-24 18:00	8,926.00 (+1.89%)
First quarter earnings results for 2026	2026-04-24 17:00	8,926.00 (+1.89%)
General meeting for 2025	2026-03-26 10:00	8,462.00 (-0.73%)
Annual report for 2025	2026-03-25	8,224.00 (+0.82%)

Show

Entries

Chugai Pharmaceutical Co Ltd Frequently Asked Questions

What is Chugai Pharmaceutical Co Ltd(TSE:4519)'s stock price today?

The current price of TSE:4519 is 円7230.00. The 52 week high of TSE:4519 is 円10700.00 and 52 week low is 円5942.00.

When is next earnings date of Chugai Pharmaceutical Co Ltd(TSE:4519)?

The next earnings date of Chugai Pharmaceutical Co Ltd(TSE:4519) is 2026-07-24.

Does Chugai Pharmaceutical Co Ltd(TSE:4519) pay dividends? If so, how much?

The Dividend Yield % of Chugai Pharmaceutical Co Ltd(TSE:4519) is 1.87% (As of Today), Highest Dividend Payout Ratio of Chugai Pharmaceutical Co Ltd(TSE:4519) was 0.53. The lowest was 0.31. And the median was 0.41. The Forward Dividend Yield % of Chugai Pharmaceutical Co Ltd(TSE:4519) is 1.79%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain	2023-03-02
	Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology	2020-07-21
	Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology	2020-07-21

10/Page

Articles on Chugai Pharmaceutical Co Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.